ResMed does some spring cleaning

Monday, May 23, 2011

SAN DIEGO - ResMed this week announced a reorganization that, among other things, creates a new business unit: ResMed Ventures and Initiatives.

ResMed Ventures and Initiatives will focus on opportunities in disease states related to sleep disordered breathing (SDB) and other market opportunities. JC Kyrillos will lead the unit as president.

"We are passionate about addressing the widespread ignorance which exists concerning the strong correlation between untreated SDB and such co-morbidities as cardiac disease," stated Chairman and CEO Peter Farrell in a release. "We have clinical data to show that treating SDB with nasal CPAP actually ameliorates and, in some cases, reverses the complications associated with these disease states, when SDB is present. To this end, we have elected to reorganize certain business units and management responsibilities to more effectively align our activities with our strategic goals."

ResMed Ventures and Initiatives will initially focus on SDB diagnostic and treatment opportunities in patients with concomitant cardiac disease and metabolic syndrome/Type 2 diabetes. Additionally, it will focus on treating SDB in the perioperative care environment and using dental appliances to treat mild to moderate SDB.

As part of the reorganization, ResMed will also combine three existing business units into two units:

*    Don Darkin will lead the combination of the former sleep and patient interface organizations as president of the SDB Strategic Business Unit.

*    Geoff Neilson will lead the new Respiratory Care Strategic Business Unit, which will focus on COPD.

ResMed will continue to operate a worldwide supply organization and three geographic commercial regions led by Robert Douglas as president, Asia Pacific, and chief, global supply operations; Stein Jacobsen as president, Europe; and Michael Farrell as president, Americas.

It will also continue to have four corporate staff functions reporting to the CEO led by Brett Sandercock as CFO; Michael Zill as CIO; David Pendarvis as chief administrative officer and global general counsel; and Jim Hollingshead as chief strategy officer.

ResMed's new management structure repositions existing senior executives. There are no new hires.